HUP0301167A3 - Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use - Google Patents

Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use

Info

Publication number: HUP0301167A3
Authority: HU; Hungary
Prior art keywords: sulfonyl; preparation; treatment; pharmaceutical compositions; compositions containing
Prior art date: 2000-06-30

Application number

HU0301167A

Other languages

English (en)

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-30

Filing date

2001-06-22

Publication date

2009-12-28

2001-06-22 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2003-08-28 Publication of HUP0301167A2 publication Critical patent/HUP0301167A2/hu

2009-12-28 Publication of HUP0301167A3 publication Critical patent/HUP0301167A3/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Obesity (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Toxicology (AREA)
Ophthalmology & Optometry (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Surgery (AREA)
Virology (AREA)

HU0301167A 2000-06-30 2001-06-22 Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use HUP0301167A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00113894		2000-06-30
PCT/EP2001/007135 WO2002002554A1 (en)	2000-06-30	2001-06-22	Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders

Publications (2)

Publication Number	Publication Date
HUP0301167A2 HUP0301167A2 (hu)	2003-08-28
HUP0301167A3 true HUP0301167A3 (en)	2009-12-28

Family

ID=8169121

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU0301167A HUP0301167A3 (en)	2000-06-30	2001-06-22	Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use

Country Status (34)

Country	Link
US (2)	US6589978B2 (hu)
EP (1)	EP1299383B1 (hu)
JP (1)	JP3994051B2 (hu)
KR (1)	KR100529423B1 (hu)
CN (1)	CN1178936C (hu)
AR (1)	AR029288A1 (hu)
AT (1)	ATE286895T1 (hu)
AU (2)	AU2001281877B2 (hu)
BR (1)	BR0112093A (hu)
CA (1)	CA2413243A1 (hu)
CZ (1)	CZ2003280A3 (hu)
DE (1)	DE60108394T2 (hu)
DK (1)	DK1299383T3 (hu)
EC (1)	ECSP024403A (hu)
ES (1)	ES2234869T3 (hu)
HR (1)	HRP20021023B1 (hu)
HU (1)	HUP0301167A3 (hu)
IL (2)	IL153425A0 (hu)
JO (1)	JO2384B1 (hu)
MA (1)	MA26923A1 (hu)
MX (1)	MXPA02012270A (hu)
MY (1)	MY126903A (hu)
NO (1)	NO324218B1 (hu)
NZ (1)	NZ523025A (hu)
PE (1)	PE20020103A1 (hu)
PL (1)	PL360396A1 (hu)
PT (1)	PT1299383E (hu)
RU (1)	RU2272026C2 (hu)
SI (1)	SI1299383T1 (hu)
TW (1)	TWI265928B (hu)
UY (1)	UY26812A1 (hu)
WO (1)	WO2002002554A1 (hu)
YU (1)	YU99702A (hu)
ZA (1)	ZA200209966B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040171614A1 (en) *	2002-02-06	2004-09-02	Schering-Plough Corporation	Novel gamma secretase inhibitors
US7256186B2 (en)	2002-02-06	2007-08-14	Schering Corporation	Gamma secretase inhibitors
TW200302717A (en)	2002-02-06	2003-08-16	Schering Corp	Novel gamma secretase inhibitors
DE10240818A1 (de) *	2002-08-30	2004-05-13	Grünenthal GmbH	Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate
GB0225938D0 (en) *	2002-11-06	2002-12-11	Glaxo Group Ltd	Novel compounds
JP2007531742A (ja) *	2004-04-05	2007-11-08	シェーリング　コーポレイション	新規のγセクレターゼインヒビター
CA2567343A1 (en) *	2004-05-20	2005-12-01	Elan Pharmaceuticals, Inc.	N-cyclic sulfonamido inhibitors of gamma secretase
EP1789404B1 (en)	2004-06-30	2010-03-24	Schering Corporation	Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors
ATE491693T1 (de) *	2004-07-22	2011-01-15	Schering Corp	Substituierte amide als inhibitoren der beta- sekretase
KR101178747B1 (ko)	2004-09-30	2012-09-03	다케다 야쿠힌 고교 가부시키가이샤	프로톤 펌프 저해제
KR20070118103A (ko) *	2005-04-04	2007-12-13	다케다 야쿠힌 고교 가부시키가이샤	우울증 또는 불안신경증의 예방 또는 치료제
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1928437A2 (en)	2005-08-26	2008-06-11	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
PT1919865E (pt)	2005-08-30	2011-07-11	Takeda Pharmaceutical	Derivados de 1h-pirrole substituídos com 1-heterociclilsulfonilo, 2-aminometilo, 5-(hetero)arilo como inibidores da secreção ácida
JP2009512711A (ja)	2005-10-21	2009-03-26	ブレインセルス，インコーポレイティド	Ｐｄｅ阻害による神経新生の調節
WO2007053596A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2026813A2 (en)	2006-05-09	2009-02-25	Braincells, Inc.	5 ht receptor mediated neurogenesis
WO2007134136A2 (en)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenesis by modulating angiotensin
WO2008030651A1 (en)	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
AU2007304475B2 (en) *	2006-09-29	2012-07-26	Grunenthal Gmbh	Substituted sulfonamide derivatives
US8933105B2 (en)	2007-02-28	2015-01-13	Takeda Pharmaceutical Company Limited	Pyrrole compounds
US8673961B2 (en) *	2008-08-15	2014-03-18	N30 Pharmaceuticals, Inc.	Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents
PT2318390E (pt)	2008-08-27	2013-07-10	Takeda Pharmaceutical	Compostos de pirrole
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
ES2351323B1 (es) *	2009-06-26	2011-10-05	Institut Univ. De Ciència I Tecnologia, S.A.	Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para el descubrimiento de farmacos.
ES2351452B1 (es) *	2009-07-01	2011-10-05	Institut Univ. De Ciència I Tecnologia, S.A.	Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica.
EP4361148A4 (en) *	2021-06-25	2025-07-09	Albius Sciences Alpha Private Ltd	HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVE USED AS A MEDICAMENT FOR THE TREATMENT AND/OR PREVENTION OF AN INFECTIOUS DISEASE DUE TO RS VIRUS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3905979A (en) *	1974-05-09	1975-09-16	Stanford Research Inst	Diazabicyclooctanes and diazabicycloheptanes
US4539411A (en) *	1982-02-05	1985-09-03	Hoffmann-La Roche Inc.	Rhodium complexes of chiral phosphines
US5036153A (en) *	1989-05-11	1991-07-30	Braish Tamim F	Preparation of 2,5-diazabicyclo[2.2.1]heptanes and intermediates
US6417198B1 (en) *	1993-12-21	2002-07-09	Eli Lilly And Company	Methods of inhibiting CNS problems in post-menopausal women
GB9612884D0 (en)	1996-06-20	1996-08-21	Smithkline Beecham Plc	Novel compounds
US5721256A (en)	1997-02-12	1998-02-24	Gpi Nil Holdings, Inc.	Method of using neurotrophic sulfonamide compounds
WO1999026615A1 (en)	1997-11-24	1999-06-03	Merck & Co., Inc.	Cyclic amino acid derivatives as cell adhesion inhibitors
US6645939B1 (en) *	1997-11-24	2003-11-11	Merck & Co., Inc.	Substituted β-alanine derivatives as cell adhesion inhibitors
GB9804426D0 (en)	1998-03-02	1998-04-29	Pfizer Ltd	Heterocycles
AT411339B (de)	1998-05-13	2003-12-29	Fronius Schweissmasch Prod	Verfahren zum steuern eines schweissgerätes und steuervorrichtung hierfür
SK18202000A3 (sk)	1998-06-03	2001-07-10	Gpi Nil Holdings, Inc.	Aza-heterocyklické zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie
CA2354774C (en)	1998-12-18	2009-05-26	Schering Corporation	Farnesyl protein transferase inhibitors
EA200100815A1 (ru) *	1999-01-27	2002-08-29	Орто-Макнейл Фармасьютикал, Инк.	Пептидильные гетероциклические кетоны, применимые в качестве ингибиторов триптазы
TW575561B (en) *	1999-03-25	2004-02-11	Hoffmann La Roche	1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives
ES2296618T3 (es) *	1999-05-20	2008-05-01	Dong Wha Pharmaceutical Industrial Co. Ltd.	Derivados opticamente activos de acidos quinolin-carboxilicos que tienen sustituyentes de 7-pirrolidina que provocan actividad optica y un procedimiento para la preparacion de estos.
US6143776A (en) *	2000-02-02	2000-11-07	Sunesis Pharmaceuticals, Inc.	Tosylproline analogs as thymidylate synthase inhibitors

2001
- 2001-06-13 US US09/880,539 patent/US6589978B2/en not_active Expired - Fee Related
- 2001-06-14 TW TWSULFONYL-A patent/TWI265928B/zh not_active IP Right Cessation
- 2001-06-22 CA CA002413243A patent/CA2413243A1/en not_active Abandoned
- 2001-06-22 AU AU2001281877A patent/AU2001281877B2/en not_active Ceased
- 2001-06-22 MX MXPA02012270A patent/MXPA02012270A/es active IP Right Grant
- 2001-06-22 EP EP01960365A patent/EP1299383B1/en not_active Expired - Lifetime
- 2001-06-22 CZ CZ2003280A patent/CZ2003280A3/cs unknown
- 2001-06-22 AU AU8187701A patent/AU8187701A/xx active Pending
- 2001-06-22 CN CNB01812061XA patent/CN1178936C/zh not_active Expired - Fee Related
- 2001-06-22 ES ES01960365T patent/ES2234869T3/es not_active Expired - Lifetime
- 2001-06-22 DE DE60108394T patent/DE60108394T2/de not_active Expired - Fee Related
- 2001-06-22 IL IL15342501A patent/IL153425A0/xx active IP Right Grant
- 2001-06-22 HU HU0301167A patent/HUP0301167A3/hu unknown
- 2001-06-22 PT PT01960365T patent/PT1299383E/pt unknown
- 2001-06-22 SI SI200130290T patent/SI1299383T1/xx unknown
- 2001-06-22 AT AT01960365T patent/ATE286895T1/de not_active IP Right Cessation
- 2001-06-22 JP JP2002507806A patent/JP3994051B2/ja not_active Expired - Fee Related
- 2001-06-22 DK DK01960365T patent/DK1299383T3/da active
- 2001-06-22 PL PL36039601A patent/PL360396A1/xx unknown
- 2001-06-22 KR KR10-2002-7017967A patent/KR100529423B1/ko not_active Expired - Fee Related
- 2001-06-22 NZ NZ523025A patent/NZ523025A/en unknown
- 2001-06-22 WO PCT/EP2001/007135 patent/WO2002002554A1/en not_active Ceased
- 2001-06-22 RU RU2003100516/04A patent/RU2272026C2/ru not_active IP Right Cessation
- 2001-06-22 HR HR20021023A patent/HRP20021023B1/xx not_active IP Right Cessation
- 2001-06-22 YU YU99702A patent/YU99702A/sh unknown
- 2001-06-22 BR BR0112093-0A patent/BR0112093A/pt not_active IP Right Cessation
- 2001-06-26 JO JO2001100A patent/JO2384B1/en active
- 2001-06-27 AR ARP010103053A patent/AR029288A1/es not_active Application Discontinuation
- 2001-06-27 MY MYPI20013048 patent/MY126903A/en unknown
- 2001-06-27 PE PE2001000638A patent/PE20020103A1/es not_active Application Discontinuation
- 2001-06-29 UY UY26812A patent/UY26812A1/es not_active Application Discontinuation
2002
- 2002-12-09 ZA ZA200209966A patent/ZA200209966B/en unknown
- 2002-12-12 IL IL153425A patent/IL153425A/en not_active IP Right Cessation
- 2002-12-26 EC EC2002004403A patent/ECSP024403A/es unknown
- 2002-12-27 MA MA26983A patent/MA26923A1/fr unknown
- 2002-12-27 NO NO20026263A patent/NO324218B1/no unknown
2003
- 2003-03-26 US US10/397,908 patent/US6995182B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NO20026263D0 (no)	2002-12-27
KR20030011378A (ko)	2003-02-07
JO2384B1 (en)	2007-06-17
EP1299383B1 (en)	2005-01-12
CA2413243A1 (en)	2002-01-10
RU2272026C2 (ru)	2006-03-20
PL360396A1 (en)	2004-09-06
ES2234869T3 (es)	2005-07-01
HK1058358A1 (en)	2004-05-14
TWI265928B (en)	2006-11-11
ATE286895T1 (de)	2005-01-15
SI1299383T1 (en)	2005-06-30
AR029288A1 (es)	2003-06-18
MXPA02012270A (es)	2003-04-25
DE60108394D1 (de)	2005-02-17
US6589978B2 (en)	2003-07-08
DK1299383T3 (da)	2005-05-23
US20020019424A1 (en)	2002-02-14
US6995182B2 (en)	2006-02-07
CZ2003280A3 (cs)	2003-12-17
HRP20021023B1 (en)	2006-08-31
IL153425A (en)	2007-08-19
PE20020103A1 (es)	2002-02-13
KR100529423B1 (ko)	2005-11-17
HUP0301167A2 (hu)	2003-08-28
NO20026263L (no)	2002-12-27
JP2004502688A (ja)	2004-01-29
HRP20021023A2 (en)	2004-08-31
AU2001281877B2 (en)	2006-08-31
ZA200209966B (en)	2004-03-09
IL153425A0 (en)	2003-07-06
CN1178936C (zh)	2004-12-08
MY126903A (en)	2006-10-31
JP3994051B2 (ja)	2007-10-17
YU99702A (sh)	2006-05-25
MA26923A1 (fr)	2004-12-20
WO2002002554A1 (en)	2002-01-10
UY26812A1 (es)	2001-12-28
BR0112093A (pt)	2003-05-13
CN1440405A (zh)	2003-09-03
EP1299383A1 (en)	2003-04-09
DE60108394T2 (de)	2006-03-02
ECSP024403A (es)	2003-02-06
AU8187701A (en)	2002-01-14
NZ523025A (en)	2004-04-30
PT1299383E (pt)	2005-05-31
NO324218B1 (no)	2007-09-10
US20030212066A1 (en)	2003-11-13

Publication	Publication Date	Title
HUP0301167A3 (en)	2009-12-28	Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use
HUP0204399A3 (en)	2004-11-29	Pteridine compounds for the treatment of psoriasis, process for their preparation, pharmaceutical compositions containing them and their use
HUP0301046A3 (en)	2008-12-29	Quinazoline derivatives for the treatment of tumours, process for their preparation and pharmaceutical compositions containing them
IL163102A (en)	2011-07-31	Dihydrobenzodiazepin-2-one derivatives, process for their preparation and use thereof in the preparation of medicaments for the treatment of neurological disorders
HUP0203142A3 (en)	2003-03-28	Benzodiazepine derivatives, process for preparation of the compounds, pharmaceutical compositions containing them and their use
HUP0401086A3 (en)	2011-07-28	4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for preparation of pharmaceutical compositions for the treatment of pain, anxiety or gastrointestinal disorders and process for preparation the compounds
IL219397A0 (en)	2012-06-28	Compounds for the treatment of metabolic disorders, methods of preparing same, and pharmaceutical compositions containing same
HUP0204226A3 (en)	2003-07-28	Quinazoline derivatives, pharmaceutical compositions containing them, their use and process for the preparation of the compounds
HUP0104867A3 (en)	2002-06-28	Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use
HUP0303296A3 (en)	2006-04-28	Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours, process for their preparation and pharmaceutical compositions containing them
IL157734A0 (en)	2004-03-28	Pharmaceutical compositions for the treatment of urogenital disorders
HUP0200309A3 (en)	2003-05-28	Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression, process for their preparation and pharmaceutical compositions containing them
IL147217A0 (en)	2002-11-10	New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
IL164108A (en)	2010-05-31	Quinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of medicaments for the treatment of cns and other disorders
HUP0200284A3 (en)	2003-04-28	1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders, process for their preparation and pharmaceutical compositions containing them
HUP0204245A3 (en)	2004-12-28	Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0300618A3 (en)	2003-12-29	Adamantana derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP9701193A3 (en)	2000-08-28	Use of n-(4-aryl-thiazol-2-yl)-sulfonamide derivatives for the preparation of pharmaceutical compositions treating neurological disorders, new derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0401747A3 (en)	2005-06-28	Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds
HUP0202075A3 (en)	2003-03-28	Substituted 2-dialkylaminoalkylbiphenyl derivatives, process for their preparation, pharmaceutical compositions containing them and their use
AU2001266152A1 (en)	2002-01-02	Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
HUP0202233A3 (en)	2004-12-28	Derivatives and analogues of galanthamin, their use, pharmaceutical compositions containing them and process for the preparation of them
HUP0204563A3 (en)	2004-12-28	Process for preparation of 3,3-diarylpropylamine derivatives and their intermediates and their use for preparation of pharmaceutical compositions
HUP0002963A3 (en)	2001-09-28	Use of pyrazolo-[4,3-d] pyrimidinon derivatives for the production of pharmaceutical compositions for treating diseases of the eye field
HUP0103832A3 (en)	2002-12-28	Triazolopyridines for the treatment of thrombosis disorders, pharmaceutical compositions containing the same and process for preparation thereof

Legal Events

Date	Code	Title	Description
2010-03-01	FD9A	Lapse of provisional protection due to non-payment of fees